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Background: While it is suggested that the prevalence of asthma in developed countries may have stabilized, this
is not clear in currently developing countries. Current available information for both adults and children
simultaneously on the burden and impact of allergic conditions in Colombia and in many Latin American countries
is limited. The objectives of this study were to estimate the prevalence for asthma, allergic rhinitis (AR), atopic
eczema (AE), and atopy in six colombian cities; to quantify costs to the patient and her/his family; and to determine
levels of Immunoglobulin E (IgE) in asthmatic and healthy subjects.
Methods: We conducted a cross-sectional, population-based study in six cities during the academic year 2009–2010. We
used a school-based design for subjects between 5–17 years old. We carried out a community-based strategy for subjects
between 1–4 years old and adults between 18–59 years old. Serum samples for total and antigen-specific (IgE) levels were
collected using a population-based, nested, case–control design.
Results: We obtained information on 5978 subjects. The largest sample of subjects was collected in Bogotá (2392).
The current prevalence of asthma symptoms was 12% (95% CI, 10.5-13.7), with 43% (95% CI, 36.3-49.2) reporting
having required an emergency department visit or hospitalization in the past 12 months. Physician diagnosed
asthma was 7% (95% CI, 6.1-8.0). The current prevalence of AR symptoms was 32% (95% CI, 29.5-33.9), and of AE
symptoms was 14% (95% CI, 12.5-15.3). We collected blood samples from 855 subjects; 60.2% of asthmatics and
40.6% of controls could be classified as atopic.
Conclusions: In Colombia, symptom prevalence for asthma, AR and AE, as well as levels of atopy, are substantial.
Specifically for asthma, symptom severity and absence from work or study due to symptoms are important. These primary
care sensitive conditions remain an unmet public health burden in developing countries such as Colombia.Background
There is data from epidemiological studies, mostly from
middle and high income countries, that suggests the disease
burden due to asthma may have stabilized or even
decreased [1-3]. It is not clear, however, if the same ten-
dency would be observed in low to middle income coun-
tries, or by that matter, for allergic rhinitis (AR) and atopic
eczema (AE) as well [4-6]. Additionally, “new” associations,
potentially causal, may keep disease burden increasing in
different regions [7-13].* Correspondence: rjdennis@cardioinfantil.org
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medium, provided the original work is properlyGiven the potentially inaccurate inferences when extrapo-
lating research findings from different countries, especially
on allergic conditions where the “drivers” of risk may be
substantially different and vary dramatically among regions
of the same country [14], it is crucial to have national esti-
mates of epidemiological trends in these conditions. This is
particularly important in Latin America, where the diversity
of environmental conditions is high [15]. Colombia is a
country of over 41 million inhabitants, predominantly
urban (72%), where about 30% live in the four largest cities
(Bogota, Medellin, Cali and Barranquilla). Similar to other
countries in the Andean region (Venezuela, Ecuador, Peru,
Bolivia), Colombia is experimenting changes consistent with
a society in transition, with an aging population, where theLtd. This is an Open Access article distributed under the terms of the Creative Commons
/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any
cited.
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life expectancy, mortality rates and other basic health indi-
cators are closer to those of Peru and Ecuador [16].
For Colombia, while previous research on asthma and
other allergic conditions can serve as a good base for com-
parisons [5,6,17-19], there is limited information available
for both adults and children simultaneously on the current
burden and impact of allergic conditions. This is the case as
well for many Latin American countries, and certainly for
those in the Andean and Caribbean regions.
The objectives of this study were to estimate the current
prevalence of asthma, AR, AE and atopy in six colombian
cities; to quantify costs to the patient and her/his family;
and to determine levels of Immunoglobulin E (IgE) in asth-
matic and healthy subjects.
Methods
Study design
We conducted a cross-sectional, population-based sur-
vey with an ancillary nested case–control study, in six
Colombian cities: Barranquilla, Bogotá, Bucaramanga,
Cali, Medellin, and San Andrés Island. Inclusion criteria
were men or women aged 1–59 years old. Exclusion cri-
teria included: (i) people confined in acute care hospitals
or institutions for the chronically ill or for the disabled
at the time of the study, and (ii) people with an altered
mental state, dementia, or mentally challenged, because
of the difficulty in collecting and assuring validity of infor-
mation. The protocol was approved by the Clinical Research
Ethics Committee at Fundación Cardioinfantil-Instituto de
Cardiología in Bogotá, Colombia (IORG0006438).
Sampling frame and sampling strategy
The sampling strategy differed based on subject age.
First, we used a school-based design with a multistage
cluster sampling to select children and adolescents (5–
17 years old) that included representative samples
from both private and public schools. The 2007 Co-
lombian census was used as the sampling frame for
randomization [20]. Since enrollment information was
not available from all schools, two multistage probabil-
istic sampling strategies were implemented. For those
schools with enrollment information, a probability
proportional to size without replacement was imple-
mented using enrollment for the cumulative total
method [21], within city strata, school type (private or
public), and education level. For those schools without
enrollment information, multistage probabilistic sam-
pling was carried out using simple random selection
within strata of city, school type and education level.
Within a school, a grade level was randomly selected
and then one class group was randomly selected. All
children and adolescents within the selected class
group were invited to participate. A self-administeredquestionnaire was given to adolescents (13–17 years
old) at their school. Parents of children (5–12 years
old) were interviewed at home by study personnel.
Second, we carried out a community-based strategy
to select subjects 1–4 and 18–59 years old. The homes
of the randomly selected children and adolescent from
the school-based design were considered “index” dwell-
ings. We used a systematic approach to select eligible
and consenting neighboring households close to the
“index” dwelling. We contacted different households as
necessary to include about four randomly selected sub-
jects, each one from different households, for each
“index” dwelling.
Third, we implemented a nested, case–control design
based on asthma symptoms within this population-
based study to assess the frequency of atopy. We
defined a “case” as any subjects who answered yes to
having asthma symptoms and a “control” as any subject
who (i) reported not having had symptoms of asthma,
allergic rhinitis, or atopic eczema in the last year; and
(ii) reported no previous medical diagnosis of asthma,
allergic rhinitis or atopic eczema. Additional consent to
donate a blood sample of 3–10 mL was asked to all
identified cases and controls. Cases and controls were
frequency-matched by age group, gender, and city.Sample size
Sample size calculations were based on the Colombian
population estimated from the 2005 national census
and the estimated prevalence for each of the three dis-
eases in a previous study in Colombia [17]. A sampling
error between 1%-2% and a type I error of 0.05 was
used. We estimated that 6,000 subjects proportionally
allocated by population number in all six cities could
give sufficient precision for nationwide estimates. Simi-
larly, it was calculated that close to 10% of the surveyed
subjects would be eligible for blood sampling for aller-
gen-specific IgE antibody (sIgE) testing and total IgE
(tIgE) determination [17].Questionnaire and data collection
Data collection took place during the academic year
2009–2010. The questionnaires were similar to those in
a previous study [17]. Questions used were originally
developed and validated by the International Study of
Asthma and Allergy in Children initiative (ISAAC) [22].
We included a “does not know/does not respond” op-
tion in the questionnaire, and assumed for analysis as a
“NO” answer. The calculations provided in the text and
in the tables include this proportion of responses in the
denominator of all prevalence estimates.
We added questions on absenteeism from school or
work, health care consultants, and out-of-pocket costs.
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used for prevalence estimations were the following:
Asthma symptoms in the last year: Have you (or your
child) had wheezing, or whistling in the chest in the past
12 months?
Past (lifetime) asthma symptoms: Have you (or your child)
ever had wheezing or whistling in the chest at any time in
the past?
Allergic rhinitis symptoms in the last year: In the past 12
months, have you (or your child) had a problem with
sneezing or a running or blocked nose, when you (or your
child) DID NOT have a cold or the flu?”
Past (lifetime) allergic rhinitis symptoms: Have you (or
your child) ever had a problem with sneezing or a
running or blocked nose, when you (or your child) DID
NOT have a cold or the flu?”
Atopic eczema symptoms in the last year: “Have you (or
your child) had this itchy rash at any time in the past 12
months?” and answered positively to the question, “Has
this itchy rash at any time affected any of the following
places: the folds of the elbows, behind the knees, in front
of the ankles, under the buttocks, or around the neck, ears
or eyes?”. These questions were preceded by: “Have you
(have your child) ever had a skin rash which was coming
and going for at least six months?
Past (lifetime) atopic eczema symptoms: Have you
(have your child) ever had a skin rash which was
coming and going for at least six months?
The definitions for disease severity and previous
medical diagnosis of the three conditions were identi-
cal to those previously used in other ISAAC studies
and can be found at http://isaac.auckland.ac.nz/resources/
tools.php?menu=tools1.Immunoglobulin E (IgE) analysis
Serum samples were shipped following cold-chain stan-
dards to the Institute for Immunological Research at the
University of Cartagena where all laboratory analyses took
place. For each sample, total IgE (tIgE) and allergen-specific
IgE antibody (sIgE) assays against Dermatophagoides ptero-
nyssinus and Blomia tropicalis were performed using
ImmunoCap system (Phadia) and following the technical
instructions of the manufacturer. Atopy was defined as (i)
tIgE levels greater than 100 kU/l or (ii) sIgE to Blomia tropi-
calis or Dermatophagoides pteronyssinus equal or greater
than 0.35 kUA/l.Statistical analysis
Statistical analyses were carried out at the Pontificia Univer-
sidad Javeriana in Bogotá and at the University of Texas
Health Science Center at Houston. For the random sam-
pling, weights (the inverse of the selection probability of
each observation) were calculated to account for differential
inclusion probabilities due to the complex design; for this,
information was obtained on the number of enrolled stu-
dents during the 2009–2010 academic years in combination
with the Colombian census bureau projections for year
2009. For the total sample, in addition to the previous
weights, post-stratification weight adjustments were calcu-
lated to ensure that city, age, and gender composition in the
sample was the same as in the sampling frame and census
projections. Prevalence estimates are adjusted by city, age
and gender. All the analyses took the form of weighted sta-
tistics with their 95% confidence intervals using the Taylor
series linearization method for variance estimation [23].
Weighted percentages are reported for categorical variables.
For continuous variables, weighted medians and inter-
quartile range are reported. The Wilcoxon rank-sum test
and chi-square statistics were used for statistical inference
in the nested case–control study.Results
We obtained information on 5978 subjects (Table 1). In
the school-based phase, 40.9% of schools, randomly
selected, participated. In the community-based phase,
participation ranged from 40%-70% between cities. In
the nested case–control study, 53.4% of eligible case
and 15.5% of eligible controls participated. The fre-
quency of the“does not know/does not respond” option
varied, but was below 3% for all questions in the
questionnaire.Asthma
The current prevalence of asthma symptoms varied be-
tween cities and by age group, but tended to be similar
between genders (Table 2). Overall, the prevalence was
12% (95% CI, 10.5-13.7). Variations by city and age
group, but not by sex, were also found for the lifetime
accumulated prevalence of asthma symptoms (Table 3);
the overall lifetime accumulated prevalence of asthma
symptoms was 23% (95% CI, 21.1-24.8). The overall
prevalence of physician-diagnosed asthma (Table 4) was
much lower than symptom-based prevalence (7%; 95% CI,
6.1-8.0). Disease severity was high among those reporting
asthma symptoms in the past 12 months; the prevalence
reporting night awakenings due to symptoms was 58% (95%
CI, 50.3-65.3), out of which 29% (95% CI, 23.7-34.3)
reported symptoms 1–3 nights per week in the previous
12 months. Additionally, 43% (95% CI, 36.3-49.2) of sub-
jects with reported asthma symptoms also reported
Table 1 Distribution of Subjects According to Sex, Age,
Education and City in Colombia (2009–2010, n = 5978)
Variable No. %a 95% CIb
Gender
Male 2370 48.52 46.45 50.60
Female 3608 51.48 49.40 53.55
Age, yr
1 – 4 466 7.09 6.76 7.43
5 – 17 1486 24.83 22.56 27.10
18 – 59 4026 68.08 66.01 70.15
Education
None 29 0.65 0.40 0.90
Elementary School 3582 55.96 53.99 57.92
Middle/High School 1515 29.07 27.12 31.02
Associate Degree 290 5.74 5.05 6.43
College 361 7.92 7.08 8.76
Otherc 26 0.56 0.33 0.78
Missing 5 0.11 0.01 0.21
City
Barranquilla 700 8.72 7.98 9.46
Bogotá 2392 54.00 52.00 56.00
Cali 1021 16.32 15.15 17.49
Bucaramanga 453 3.81 3.34 4.29
San Andrés 401 0.51 0.45 0.58
Medellín 1011 16.63 15.13 18.13
a Weighted Percentage (city, age and gender distribution of the general population).
b CI: Confidence Interval.
c Other: Doctorate, Masters, Police Academy, Art School, Security Training,
Technician, etc.
Table 2 Prevalence of Asthma Symptoms in the Last Year
According to Age, Sex and City in Colombia (2009 – 2010,
n = 5978)
Variable No. Yes %a 95% CIb
Age, yr
1 - 4 466 90 18.98 15.18 22.78
5 – 17 1486 256 16.78 11.30 22.26
18 - 59 4026 401 9.68 8.69 10.66
Gender
Male 2370 298 12.13 9.41 14.86
Female 3608 448 12.07 10.47 13.67
City
Barranquilla 700 119 14.52 11.85 17.19
Bogotá 2392 281 11.35 9.43 13.27
Cali 1021 133 13.35 10.98 15.72
Bucaramanga 453 72 13.95 10.00 17.89
San Andrés 401 42 11.70 7.38 16.02
Medellín 1011 99 11.63 5.20 18.06
Overall c 5978 747 12.10 10.54 13.66
a Weighted Percentage (city, age and gender distribution of the general population).
b CI: Confidence Interval.
c Adjusted by age, sex and city.
Table 3 Lifetime Prevalence of Asthma Symptoms
According to Age, Sex, and City in Colombia (2009–2010,
n = 5978)
Variable No. Yes %a 95% CIb
Age, yr
1 - 4 466 175 36.51 31.83 41.19
5 – 17 1486 469 30.48 24.14 36.81
18 - 59 4026 780 18.83 17.52 20.14
Gender
Male 2370 584 22.85 19.95 25.75
Female 3608 840 23.09 20.72 25.46
City
Barranquilla 700 169 22.10 18.74 25.45
Bogotá 2392 527 21.71 19.04 24.38
Cali 1021 283 26.22 23.18 29.26
Bucaramanga 453 137 28.37 23.12 33.63
San Andrés 401 91 23.09 17.93 28.26
Medellín 1011 217 23.13 17.10 29.16
Overall c 5978 1424 22.97 21.11 24.83
a Weighted Percentage (city, age and gender distribution of the general population).
b CI: Confidence Interval.
c Adjusted by age, sex and city.
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in the last year.Allergic rhinitis
There was a tendency in the current prevalence of AR
symptoms to vary between cities and by age group (greatest
in those 5–17 years old) (Table 5). Overall, the prevalenceTable 4 Prevalence of Physician-Diagnosed Asthma
According to Age, Sex and City in Colombia (2009–2010,
n = 5978)
Variable No. Yes %a 95% CIb
Age, yr
1 - 4 466 52 9.19 6.52 11.86
5 – 17 1486 149 8.59 5.50 11.68
18 - 59 4026 280 6.30 5.50 7.09
Gender
Male 2370 201 6.98 5.51 8.45
Female 3608 280 7.16 5.92 8.39
City
Barranquilla 700 76 9.98 7.57 12.39
Bogotá 2392 137 5.84 4.36 7.30
Cali 1021 86 8.66 6.51 10.82
Bucaramanga 453 53 10.29 7.10 13.49
San Andrés 401 46 11.28 7.34 15.21
Medellín 1011 83 7.11 5.19 9.02
Overall c 5978 481 7.07 6.12 8.02
a Weighted Percentage (city, age and gender distribution of the general population).
b CI: Confidence Interval.
c Adjusted by age, sex and city.
Table 5 Prevalence of Allergic Rhinitis Symptoms in the
Last Year According to Age, Sex and City in Colombia
(2009–2010, n = 5978)
Variable No. Yes %a 95% CIb
Age, yr
1 - 4 466 145 30.44 25.96 34.91
5 – 17 1486 655 46.93 40.00 53.85
18 - 59 4026 1099 26.31 24.84 27.79
Gender
Male 2370 749 31.07 27.63 34.52
Female 3608 1150 32.34 29.52 35.16
City
Barranquilla 700 220 28.73 24.98 32.49
Bogotá 2392 758 32.61 29.16 36.05
Cali 1021 283 26.54 23.48 29.60
Bucaramanga 453 183 39.48 33.42 45.53
San Andrés 401 128 30.82 25.33 36.30
Medellín 1011 327 33.77 28.11 39.42
Overall c 5978 1899 31.72 29.51 33.94
a Weighted Percentage (city, age and gender distribution of the general population).
b CI: Confidence Interval.
c Adjusted by age, sex and city.
Table 6 Prevalence of Atopic Eczema Symptomsc, in the
Last Year According to Age, Sex and City in Colombia
(2009–2010, n = 5978)
Variable No. Yes %a 95% CIb
Age, yr
1 - 4 466 102 19.53 15.76 23.30
5 – 17 1486 307 18.99 14.06 23.92
18 - 59 4026 478 11.45 10.39 12.51
Gender
Male 2370 334 12.39 10.64 14.14
Female 3608 553 15.31 13.08 17.55
City
Barranquilla 700 85 11.02 8.42 13.62
Bogotá 2392 335 13.60 11.25 15.95
Cali 1021 151 13.50 10.97 16.03
Bucaramanga 453 81 16.21 11.95 20.47
San Andrés 401 59 13.69 9.89 17.49
Medellín 1011 176 16.23 13.36 19.10
Overall d 5978 887 13.89 12.45 15.33
a Weighted Percentage (city, age and gender distribution of the general population).
b CI: Confidence Interval.
c Itchy rash during the last year affecting at least one of the characteristic places
on body.
d Adjusted by age, sex and city.
Table 7 Disease Burden Associated with Asthma, Allergic
Rhinitis, and Atopic Eczema in Colombia (2009–2010)





Asthma 67.0 39,957 (80,756)
Allergic Rhinitis 56.7 25,613 (43,098)
Atopic Eczema 62.8 19,765 (47,577)
Subjects reporting days away
from work/school,
past 6 months
Asthma 55.7 3.98 (5.4)
Allergic Rhinitis 32.9 2.78 (3.5)
Atopic Eczema 17.7 4.52 (5.9)
Caregiver´s with days away
from work/school,
past 6 months
Asthma 43.4 2.96 (5.5)
Allergic Rhinitis 26.8 2.29 (4.0)
Atopic Eczema 13.0 4.74 (11.6)
Subjects reporting physician
consultations, past 12 months
Asthma 71.7 n/ad
Allergic Rhinitis 60.5 n/ad
Atopic Eczema 64.1 n/ad
a Weighted Percentage of those subjects with disease symptoms in the previous
12 months.
b Colombian pesos of 2009.
c IQR: Interquartile range.
d n/a: not applicable.
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prevalence of AR symptoms was 38% (95% CI, 35.9-40.3).
Among subjects reporting AR symptoms in the last year,
the prevalence of physician diagnosed AR was 14% (95% CI,
12.4-16.1). The prevalence of allergic rhinoconjunctivitis
during the previous year was 20% (95% CI, 19.0-21.0).
Atopic eczema
The prevalence of AE symptoms in the last 12 months
tended to vary little between cities or by age group, but
tended to be larger for females (Table 6). Overall, the
prevalence of AE in the last 12 months was 14% (95% CI,
12.5-15.3). The lifetime prevalence of AE symptoms was
24% (95% CI, 21.0-26.3), and the prevalence of physician
diagnosed AE was 6% (95% CI, 4.8-6.3). The prevalence of
those reporting one or more night awakenings per week in
the previous year due to AE symptoms was 13% (95% CI,
9.3-15.9).
Disease burden
Asthma was clearly the condition that generated the largest
amount of out-of-pocket monthly expenditures (reported
by 67% of asthmatic subjects). Asthma was also responsible
for the highest frequency of reported absenteeism within
the last six months from work or school, both for subjects
and caregivers (Table 7); the median value of days away
from school/work referred by asthma subjects was 4 days
and 3 days for caregivers in the previous 6 months due
to asthma. The most frequent cause for physician con-
sultations within the past year was due to asthma symp-
toms (72%; 95% CI, 63.2-80.2).Atopy
We were able to collect blood samples from 855 sub-
jects; 399 with asthma symptoms in the last year, and
456 controls. Table 8 shows that levels of tIgE and sIgE
(against Dermatophagoides pteronyssinus and Blomia tro-
picalis) were higher among cases than controls. Sixty
percent of cases and 41% of controls were classified as
atopic. Subjects with asthma symptoms and with current
Table 8 Total IgE and Specific IgE Against Blomia
tropicalis and Dermatophagoides pteronyssinus Levels by
Case or Control Status in Colombia (2009–2010)
Description Asthma Cases Controls P-value
n= 399 n= 456
Total IgE (kU/l), median (IQRa) 122.0 (340.80) 50.3 (121.00) <0.0001b
Subjects above cutoffc, No. (%) 212 (53.13%) 149 (32.68%) <0.0001d
Specific IgE BT (kUA/l),
median (IQRa)
0.1 (4.11) 0.01 (0.15) <0.0001b
Subjects above cutoffe, No. (%) 164 (41.10%) 89 (19.52%) <0.0001d
Specific IgE DP (kUA/l),
median (IQRa)
0.15 (12.48) 0.03 (0.14) <0.0001b
Subjects above cutoffe, No. (%) 184 (46.12%) 95 (20.83%) <0.0001d
a IQR: Interquartile range.
b Wilcoxon rank-sum test.
c Cutoff level: Total IgE 100 kU/l.
d Chi-square test.
e Cutoff level: Specific IgE 0.35 kUA/l.
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63% (95%CI: 53%-72.5%).
Discussion
This cross-sectional study describes the prevalence of
asthma, AR and AE symptoms in six Colombian cities,
as well as their severity and burden. It provides as well
the prevalence of atopy in asthmatic subjects, and in
subjects without these conditions. The study is import-
ant because it is able to provide this information in sub-
jects between 1 and 59 years of age. Additionally, this
study is uniquely poised to generate vital surveillance in-
formation in Colombia, and increases the understanding
of the public health burden due to these conditions in
developing countries.
The current study used the same questions as the
ISAAC initiative worldwide, and was conducted in the
same cities in Colombia as a previous study from the
same research group eleven years ago [17]. However, dif-
ferences in age groups, methods and in data analysis, as
well as in allergens used for sIgE, preclude a formal com-
parison between the two surveys, or with others con-
ducted previously in Colombia and abroad. Thus,
contrasts discussed here can only suggest potential ten-
dencies over time. Our study suggests that the preva-
lence of symptoms of all three conditions is increasing in
Colombia. This tendency towards an increase is similar
to that found in ISAAC studies over an average of 8 years
in the region; for the 13–14 age group, Latin America was
one of the few regions in the world (with Africa) that had
more centres increasing prevalence of all three diseases
simultaneously [4]. The wide variations observed in this
study in the prevalence of the three conditions, as well as
those observed between cities and for the different age
groups, have been found previously elsewhere [24], as well
as for Latin American countries [25]. These differencessuggest that local factors may dramatically alter the preva-
lence of these conditions, and they can include a wide
number of both genetic and environmental characteristics
acting simultaneously and synergistically. The study by
Mallol et al [25] that included three cities in Colombia
(Bogota, Cali, Barranquilla), did not find a positive associa-
tions between asthma and the socioeconomic variables
studied (latitude, altitude, national gross income, poverty).
The Isaac III study in Bogota, however, found that asthma
symptoms were correlated with the presence of a cat in
the home, higher maternal education, watching televison 1
to 2 hours per day, and the use of acetaminophen and
antibiotics in the last year [18]. In that same study, rhino-
conjunctivitis symptoms were associated with previous
acetaminophen and antibiotic use, and higher maternal
education and cesarean birth [26]. Additional risk factors
in Latin America have also been postulated and described
in detail by Cooper et al elsewhere [27,28].
The prevalence of current asthma symptoms (12%)
seems to have increased in Colombia with respect to
results obtained 11 years ago (10%) [16]. The age group
where asthma symptoms where most frequent in both
surveys is the 1–4 year old group. It is likely that some
of these symptoms correspond to wheezing episodes
associated with respiratory viral infections early in life
[29]; recent evidence, however, also suggest that bron-
chial obstruction during acute respiratory infection in
childhood is clearly associated with subsequent asthma,
especially among school-aged children at risk for
repeated asthma exacerbations [30], making it relevant
to quantify and to include in epidemiological studies. In
the current survey we found an increase in current
asthma symptoms for those subjects 5–17 years of age.
In the ISAAC I-III 13–14 age group, similar increases
were found in Latin America for Mexico, Costa Rica,
Panama, Chile, and Argentina [4].
Disease severity for asthma remains high when com-
pared with results 11 years ago. This may be due to
under-diagnosis of asthma; in both surveys, the frequency
of physician diagnosis is very low when compared to
symptom-based prevalence, especially for subjects below
age 18 years of age, suggesting limited access to specialized
health care in these age groups. Suboptimal asthma con-
trol can be another explanation for persistent disease se-
verity, due to lack of general physician awareness on
current guidelines on effective treatment strategies for
asthma [31,32]. Disease burden to the patient and the
caregiver was important in our study, with more of 60% of
asthma patients reporting out-of-pocket expenses. In-
appropriate ambulatory care of subjects with asthma can
also be associated with increased hospitalization due to
exacerbations; asthma is an ambulatory care sensitive con-
dition where the need for hospitalization can be a marker
of inappropriate health care [33]. Additionally, the mean
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consistent with moderate persistent asthma, a stage of se-
verity associated with substantial health care costs and
hospitalizations in previous studies in the literature
[34,35].
While the presence of asthma independent of increased
IgE levels is not uncommon [36], the majority (60%) of
subjects with asthma symptoms in the past year met the
criteria for atopy in our study. This is lower than the fre-
quency obtained in the previous study in 1999 (76%), but
still high. The frequency of atopy may vary between
regions and countries, which is expected because it
depends on environmental and genetic factors [37]. There
were statistically significant differences in atopy between
cases and a control group in our study. In our population,
the high frequency of atopy among controls may be
explained in part because of exposure to helminths,
mainly Ascaris lumbricoides infections, early in life [38].
Nematode exposure induces specific IgE responses and
increases total IgE levels. In the tropics, permanent expos-
ure to mite allergens and parasite infections during child-
hood may induce sIgE to cross-reacting allergens from
mites and Ascaris [39,40].
The prevalence of AR symptoms also seems to have
increased with respect to the previous study (from 23%
to 32%) [17], but with a modest increase compared to a
more recent survey in three Colombian cities that used
the same ISAAC methodology during 2002 [41]. The lar-
ger increase in AR symptoms (than that seen for asthma
symptoms) is in line with the ISAAC I-III comparisons
in Latin America, where more centres had an increase
for AR than for asthma [4]. With 28% current prevalence
of rhinoconjunctivitis in children 5–17 years old (data
not shown), Colombia would be among the countries in
the region with the largest prevalence, as detected by
ISAAC methodology [4,6,41]. Similarly, the prevalence of
AE symptoms (14%) increased markedly in comparison
to results obtained 11 years ago (4%). The current preva-
lence of AE symptoms has increased as well when com-
pared with results obtained for Colombia during 2002 in
the 6–7 and 13–14 year old population [5].
Our study has limitations. First, results may not be
extrapolated to children not attending school or living in
rural dwellings in Colombia. Second, the community-
based strategy was not random and selection bias is pos-
sible if subjects willing to participate were also more likely
to have one of the conditions under study, biasing results
towards higher disease prevalence. While we do not have
information on non-participants to evaluate this possibil-
ity, we used a systematic approach to select eligible and
consenting neighboring households, and subjects within
households were randomly selected. Third, our choice of
controls to assess differences in atopy (excluding those
with allergic rhinitis and atopic eczema) can bequestioned; while such exclusions may have biased the
prevalence of atopy in the control group below that in the
source population of cases, we believe that exclusion of
these two conditions provide a better estimate of the
prevalence of atopy in the population sampled. Fourth,
given that we used two allergens to diagnose atopy by sIgE
(extracts from D. pteronyssinus and B. tropicalis), it is pos-
sible that the effects of cross reacting antibodies were
more relevant. Differences of allergen sensitization be-
tween patients and controls could have been greater if we
had included other allergens of interest, such as Dermato-
phagoides farinae, but financial limitations and the popula-
tion-based design precluded this.Conclusions
Our results show that in contrast to more affluent coun-
tries [42-44], these allergic conditions are a significant
problem in urban cities in Colombia, that severity of
asthma is substantial, and that levels of atopy are highly
associated with asthma symptoms. Since the allergic
component of asthma seems to be important, consider-
ation should be given to its evaluation during diagnosis.
Additionally, results of this work support the increasing
evidence that the prevalence of asthma and other allergic
diseases in Latin America is high [26], even though the
climate and hygiene conditions are different than those
of industrialized countries. Future research in the field
should look for common risk factors acting at different
times in developed and developing countries.
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